NEW YORK (GenomeWeb) – Diagnostics developer Guardant Health has inked a deal with molecular data interpretation firm N-of-One to provide decision support services for its Guardant360 test.

The diagnostic uses next-generation sequencing to analyze cell-free DNA, tumor fragments shed into the blood at low concentrations. The test can be used to gauge genetic alterations driving various tumor types and can be used by doctors to inform personalized medicine strategies for patients or guide them to clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.